Le Lézard
Classified in: Health
Subject: CALENDAR OF EVENTS

Cancer Advances, Inc. Announces Abstract and Poster Presentation at ASCO GI ? Role of an anti-gastrin vaccine (PAS) in combination with a PD-1 antibody on growth and metastasis of gastric cancer


DURHAM, N.C., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will host a virtual presentation of its poster at the American Society of Clinical Oncology's (ASCO) Gastrointestinal Cancers Symposium being held from January 20-22, 2022, at the Moscone West Building in San Francisco, CA.

The researchers evaluated the effect of Cancer Advances' Polyclonal Antibody Stimulator (PAS) vaccine and PD-1 antibody therapy alone or in combination in a murine model of gastric cancer. PAS monotherapy was found to significantly decrease tumor growth rate and fibrosis in the tumor microenvironment, and to eliminate metastases. The impact of combination therapy on these factors was greater still, although PD-1 therapy alone was not significantly different from placebo. Details of the abstract and poster presentation are below:

Abstract 334: Role of an anti-gastrin vaccine (PAS) in combination with a PD-1 antibody on growth and metastasis of gastric cancer

Link to Related Publication: https://www.frontiersin.org/articles/10.3389/fonc.2021.788875/full

Presentation Date: January 20, 2022, Online

Link to Presentation: https://www.canceradvances.com/media-presentation/role-of-an-anti-gastrin-vaccine-pas-in-combination-with-a-pd-1-antibody-on-growth-and-metastases-of-gastric-cancer/

The research was conducted in collaboration with presenter, Jill P. Smith, MD, professor of medicine and oncology at Georgetown University Medical Center, through a sponsored agreement with Cancer Advances, Inc. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers.

About Cancer Advances, Inc.

Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

About Polyclonal Antibody Stimulator (PAS)

Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program.  

If your site is interested in participating in the upcoming phase 3 clinical gastric cancer study, please contact Cancer Advances at the e-mail address below.

Contact

Cancer Advances, Inc.
E-mail: [email protected]
https://www.canceradvances.com/
https://www.linkedin.com/company/cancer-advances/



These press releases may also interest you

at 19:18
Franchise Global Health Inc. ("Franchise Global" or the "Company")  (FRA: WV4A) is pleased to announce its results for the first quarter of 2022. "The Company's German reportable segment experienced strong sales and gross profit through the first...

at 19:06
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago...

at 19:05
St. Croix Hospice is proud to have earned four Gold and three Silver Aster Awards in the Home Health/Hospice group for marketing and communications materials created in 2021. The Aster Awards by Creative Images honor "excellence in healthcare...

at 18:59
Brookdale Senior Living Inc. ("Brookdale" or the "Company") announced today that Lucinda "Cindy" Baier, President and Chief Executive Officer will participate in the Jefferies Healthcare Conference Thursday, June 9, 2022. ...

at 18:36
Today, the Public Health Agency of Canada (PHAC) is confirming additional cases of monkeypox in Canada. In addition to the previously reported sixteen confirmed cases in Quebec, PHAC's National Microbiology Laboratory (NML) has confirmed another 10...

at 18:28
Cantargia (Cantargia AB) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in the phase I/IIa CANFOUR trial. The efficacy was...



News published on 19 january 2022 at 11:00 and distributed by: